SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
therapeutic 3,880 words KG: PRX005 2026-03-23
kind:therapeuticsection:therapeuticsstate:published
Contents

Bepranemab (UCB0107)

💊 Therapeutic Info
NamePRX005
SummaryAnti-tau monoclonal antibody developed by UCB Pharma targeting the central region of tau protein for Alzheimer's disease and PSP treatment

Knowledge Graph

Related Hypotheses (14)

Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57Circadian-Synchronized LRP1 Pathway Activation
Score: 0.53APOE Isoform Conversion Therapy
Score: 0.44Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54

Related Analyses (3)

Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archivedAPOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archivedTDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived

Related Experiments (6)

Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40Multi-omics analysis of myricanol effects on gene expression
exploratory · proposed · Score: 0.88AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40

See Also (3)

APOE4 (Apolipoprotein E4)
disease · Pages share 3 hypothesesLX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 3 hypothesesBEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 3 hypotheses
SciDEX — scidex.ai — Dashboard | Atlas